How to buy Allergan stock

Allergan plc (AGN) is a leading drug manufacturers-general business based in the US. It opened the day at USD$N/A after a previous close of USD$N/A. During the day the price has varied from a low of USD$N/A to a high of USD$N/A. The latest price was USD$N/A (25 minute delay). Allergan is listed on the NYSE and employs 17,400 staff. All prices are listed in US Dollars.

How to buy shares in Allergan

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Allergan. Find the stock by name or ticker symbol: AGN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Allergan reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Allergan, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Allergan. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Allergan share price

Use our graph to track the performance of AGN stocks over time.

Allergan shares at a glance

• Live prices
• Key figures

Information last updated 2021-04-17.

Open	USD$N/A
High	USD$N/A
Low	USD$N/A
Close	USD$N/A
Previous close	USD$N/A
Change	USD$N/A
Change %	N/A%
Volume	0

Information last updated 2020-06-08.

52-week range	USD$183.85 - USD$195.31
50-day moving average	USD$188.8373
200-day moving average	USD$187.6554
Wall St. target price	USD$188.33
PE ratio	N/A
Dividend yield	USD$2.96 (1.53%)
Earnings per share (TTM)	USD$-25.502

Buy Allergan shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Allergan stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Allergan plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Allergan under- or over-valued?

Valuing Allergan stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Allergan's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Allergan's PEG ratio

Allergan's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0492. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Allergan's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Allergan's EBITDA

Allergan's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$7.2 billion.

The EBITDA is a measure of a Allergan's overall financial performance and is widely used to measure a its profitability.

Allergan financials

Revenue TTM	USD$16.1 billion
Operating margin TTM	6.85%
Gross profit TTM	USD$13.7 billion
Return on assets TTM	0.74%
Return on equity TTM	-4.15%
Profit margin	-15.44%
Book value	$175.911
Market capitalisation	USD$63.7 billion

TTM: trailing 12 months

Shorting Allergan shares

There are currently 15.0 million Allergan shares held short by investors – that's known as Allergan's "short interest". This figure is 0.1% up from 15.0 million last month.

There are a few different ways that this level of interest in shorting Allergan shares can be evaluated.

Allergan's "short interest ratio" (SIR)

Allergan's "short interest ratio" (SIR) is the quantity of Allergan shares currently shorted divided by the average quantity of Allergan shares traded daily (recently around 4.7 million). Allergan's SIR currently stands at 3.22. In other words for every 100,000 Allergan shares traded daily on the market, roughly 3220 shares are currently held short.

However Allergan's short interest can also be evaluated against the total number of Allergan shares, or, against the total number of tradable Allergan shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Allergan's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Allergan shares in existence, roughly 50 shares are currently held short) or 0.0456% of the tradable shares (for every 100,000 tradable Allergan shares, roughly 46 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Allergan.

Find out more about how you can short Allergan stock.

Allergan's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Allergan.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Allergan's total ESG risk score

Total ESG risk: 39.22

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Allergan's overall score of 39.22 (as at 12/31/2018) is pretty weak – landing it in it in the 68th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Allergan is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Allergan's environmental score

Environmental score: 5.79/100

Allergan's environmental score of 5.79 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Allergan is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Allergan's social score

Social score: 24.75/100

Allergan's social score of 24.75 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Allergan is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Allergan's governance score

Governance score: 16.68/100

Allergan's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Allergan is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Allergan's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Allergan scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Allergan hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Allergan plc was last rated for ESG on: 2019-01-01.

Total ESG score	39.22
Total ESG percentile	67.52
Environmental score	5.79
Environmental score percentile	9
Social score	24.75
Social score percentile	9
Governance score	16.68
Governance score percentile	9
Level of controversy	3

Allergan share dividends

We're not expecting Allergan to pay a dividend over the next 12 months.

Have Allergan's shares ever split?

Allergan's shares were split on a 2:1 basis on 29 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Allergan shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Allergan shares which in turn could have impacted Allergan's share price.

Allergan share price volatility

Over the last 12 months, Allergan's shares have ranged in value from as little as $183.85 up to $195.31. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Allergan's is 1.1992. This would suggest that Allergan's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Allergan overview

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc. ; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc.

Frequently asked questions

• What percentage of Allergan is owned by insiders or institutions?

  Currently 0.156% of Allergan shares are held by insiders and 98.255% by institutions.

• How many people work for Allergan?

  Latest data suggests 17,400 work at Allergan.

• When does the fiscal year end for Allergan?

  Allergan's fiscal year ends in December.

• Where is Allergan based?

  Allergan's address is: Clonshaugh Business and Technology Park, Dublin, Ireland, D17 E400

• What is Allergan's ISIN number?

  Allergan's international securities identification number is: IE00BY9D5467

• What is Allergan's CUSIP number?

  Allergan's Committee on Uniform Securities Identification Procedures number is: 00507K103